Our first product – InfectiClear® confirms the absence of infection in the patient.

We investigate the patient – rather than the pathogen – allowing us to rule out infection or sepsis.

We have developed a patented set of assays using advanced machine-learning techniques to diagnose infection. Trained from blood samples collected over 15 years, these samples included thousands of patients, some of whom developed infections and sepsis. The samples were collected daily and include full clinical metadata, and they have been robustly adjudicated for true clinical disease status.

Diagnostics trained & validated using a
wealth of clinical data

0
Patients who provided blood samples
0K
Blood samples used to train & validate our assays
0
Clinical trials underpinning our programmes
0
Participating hospitals
0
Patients who provided blood samples
0K
Blood samples used to train & validate our assays
0
Clinical trials underpinning our programmes
0
Participating hospitals

How our diagnostic tests work in practice

InfectiClear® is scheduled for release in 2025, and will be available with a user-friendly, local or cloud-based software package that can be licensed from Presymptom Health. The software generates a score indicating the likelihood of infection.

This will provide clinicians with the confidence to withhold, delay, or reduce antibiotics in the event of a low-risk score.

Each generation of Infecticlear®:

  • Uses existing instrumentation

  • Includes packaged consumable cartridge for clinical staff

  • Provides user-friendly software interface providing risk score

  • Delivers a rapid result that allows real time clinical decision making

  • Is reliable with 95% accuracy

Our Pipeline of Products

Evolution & Addition

We are developing three generations of InfectiClear®: Gen 1 launches in 2025 with 3-hour results, Gen 2 offers point-of-care results in under 40 minutes, and Gen 3 reduces costs for global deployment. Additional tests are also in progress.

Generation 1

Takes 3 hours

Runs on available instrumentation in a central lab.

Generation 2

Takes <60 mins

Runs at point of care on a novel platform.

Generation 3

Takes <60 mins

Reduces cost of Gen 2 for global deployment.

Our Development

We are innovating solutions for early infection and sepsis diagnosis with a breakthrough approach that leverages 15 years of clinical research. This wealth of data will enable us to continue to ideate on our product line, reducing time to result, cost of result, and creating more opportunity for diagnostic outcomes.

We identified specific genes and biomarkers that were expressed differently between patients with infection, sepsis and other non-infectious conditions. We did this by applying proprietary machine learning and AI to our wealth of clinical data, leading to assays that can reliably predict the onset of infection and sepsis prior to clinical presentation and diagnosis.

Our Collaborators

  1. Heffernan AJ, Denny KJ. Host Diagnostic Biomarkers of Infection in the ICU: Where Are We and Where Are We Going? Curr Infect Dis Rep. 2021;23(4):1-11. doi:10.1007/S11908-021-00747-0/TABLES/2
  2. Dahm MR, Cattanach W, Williams M, et al. Communication of Diagnostic Uncertainty in Primary Care and Its Impact on Patient Experience: an Integrative Systematic Review. J Gen Intern Med. 2023;38(3):738. doi:10.1007/S11606-022-07768-Y
  3. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better Tests, Better Care: Improved Diagnostics for Infectious Diseases. Clin Infect Dis. 2013;57(Suppl 3):S139. doi:10.1093/CID/CIT578
  4. Coon ER, Maloney CG, Shen MW. Antibiotic and Diagnostic Discordance Between ED Physicians and Hospitalists for Pediatric Respiratory Illness. Hosp Pediatr. 2015;5(3):111-118. doi:10.1542/HPEDS.2014-0110
  5. Lopansri BK, Miller RR, Burke JP, et al. Physician agreement on the diagnosis of sepsis in the intensive care unit: Estimation of concordance and analysis of underlying factors in a multicenter cohort. J Intensive Care. 2019;7(1):1-17. doi:10.1186/S40560-019-0368-2/FIGURES/5
  6. Caterino JM, Leininger R, Kline DM, et al. Accuracy of Current Diagnostic Criteria for Acute Bacterial Infection in Older Adults in the Emergency Department. J Am Geriatr Soc. 2017;65(8):1802-1809. doi:10.1111/JGS.14912
  7. Filice GA, Drekonja DM, Thurn JR, et al. Diagnostic Errors that Lead to Inappropriate Antimicrobial Use. Infect Control Hosp Epidemiol. 2015;36(8):949-956. doi:10.1017/ICE.2015.113
  8. Klouwenberg PMCK, Ong DSY, Bos LDJ, et al. Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients. Crit Care Med. 2013;41(10):2373-2378. doi:10.1097/CCM.0B013E3182923712
  9. Roger PM, Martin C, Taurel M, et al. Motives for the prescription of antibiotics in the emergency department of the University Hospital Center in Nice. A prospective study. Presse Med. 2002;31(2):58-63. PMID: 11850986
    Antimicrobial resistance. (2023) https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed July 22, 2024
  10. Sabo SR, Venkatramanan A, Shorr AF. At the Intersection of Critical Care and Infectious Diseases: The Year in Review. 2024;12(3):562. doi:10.3390/biomedicines12030562
  11. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7
  12. World Bank Group. (2017) Drug-resistant infections: a threat to our economic future (Vol. 2): final report. https://documents.worldbank.org/en/publication/documents-reports/documentdetail/323311493396993758/final-report. Accessed July 10, 2024
  13. Centers for Disease Control and Prevention. (2019) Antibiotic Resistance Threats in the United States, 2019. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html. Accessed July 22, 2024
  14. Singer M, Deutschman CS, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801. doi:10.1001/JAMA.2016.0287
  15. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. doi:10.1097/01.CCM.0000217961.75225.E9
  16. Fleischmann-Struzek C, Rudd K. Challenges of assessing the burden of sepsis. Med Klin Intensivmed Notfmed. 2023;118(2):68-74. doi:10.1007/S00063-023-01088-7/FIGURES/2
  17. Lopansri BK, Miller RR, Burke JP, et al. Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort. J Intensive Care. 2019;7(1). doi:10.1186/S40560-019-0368-2

Fueling Progress:

Our Investors and Tech Collaborators

Offering expertise and resources, our investors and tech collaborators are critical in the evolution of Presymptom Health.

Our
Investors

Our
Technology Partners